Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome

Clinical Endocrinology

Volumn 76, Issue 1, 2012, Pages 119-125

  Pepene, Carmen E ^a,b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Cluj County Clinical Emergency Hospital   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; INSULIN; LIPID; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BRACHIAL ARTERY; CAROTID ARTERY; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; VASODILATATION;

ADIPOKINES; ADULT; BIOLOGICAL MARKERS; CAROTID ARTERIES; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; POLYCYSTIC OVARY SYNDROME; REGRESSION ANALYSIS; TESTOSTERONE; TUNICA INTIMA; VASODILATION; YOUNG ADULT;

EID: 83455163980     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04171.x     Document Type: Article

References (35)

1. Chan, T.F., Chen, Y.L., Chen, H.H., et al. (2007) Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertility and Sterility, 88, 401-405.
2. Pinhas-Hamiel, O., Singer, S., Pilpel, N., et al. (2009) Adiponectin levels in adolescent girls with polycystic ovary syndrome (PCOS). Clinical Endocrinology (Oxf), 71, 823-827.
3. Panidis, D., Kourtis, A., Farmakiotis, D., et al. (2003) Serum adiponectin levels in women with polycystic ovary syndrome. Human Reproduction, 18, 1790-1796. Available at: (Accessed 04 May 2011). (Pubitemid 37107549)
4. Carmina, E., Orio, F., Palomba, S., et al. (2005) Evidence for altered adipocyte function in polycystic ovary syndrome. European Journal of Endocrinology, 152, 389-394. (Pubitemid 40439491)
5. Carmina, E., Orio, F., Palomba, S., et al. (2006) Endothelial dysfunction in PCOS: role of obesity and adipose hormones. American Journal of Medicine, 119, e351-e356.
6. Escobar-Morreale, H.F., Villuendas, G., Botella-Carretero, J.I., et al. (2006) Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Human Reproduction, 21, 2257-2265. (Pubitemid 44530598)
7. Kowalska, I., Straczkowski, M., Nikolajuk, A., et al. (2007) Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Human Reproduction, 22, 1824-1829. (Pubitemid 47062747)
8. Panidis, D., Farmakiotis, D., Rousso, D., et al. (2008) Plasma visfatin levels in normal weight women with polycystic ovary syndrome. European Journal of Internal Medicine, 19, 406-412, Available at: (Accessed 04 May 2011).
9. Ducluzeau, P.H., Cousin, P., Malvoisin, E., et al. (2003) Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 88, 3626-3631. (Pubitemid 37034505)
10. Orio Jr, F., Palomba, S., Cascella, T., et al. (2003) Adiponectin levels in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 88, 2619-2623. (Pubitemid 36724434)
11. Ardawi, M.S., &, Rouzi, A.A., (2005) Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertility and Sterility, 83, 1708-1716. (Pubitemid 40824803)
12. Azziz, R., Carmina, E., Dewailly, D., et al. (2006) Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. Journal of Clinical Endocrinology and Metabolism, 91, 4237-4245. (Pubitemid 44833391)
13. Vermeulen, A., Verdonck, L., &, Kaufman, J.M., (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism, 84, 3666-3672. (Pubitemid 30645223)
14. Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419. (Pubitemid 15018832)
15. Pepene, C.E., Ilie, I.R., Marian, I., et al. (2011) Circulating osteoprotegerin and soluble receptor activator of nuclear factor {kappa}B ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. European Journal of Endocrinology, 164, 61-68.
16. Tan, K.C.B., Xu, A., Chow, W.S., et al. (2004) Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. Journal of Clinical Endocrinology and Metabolism, 88, 765-769. (Pubitemid 38269891)
17. Moschen, A.R., Kaser, A., Enrich, B., et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology, 178, 1748-1758. (Pubitemid 46154646)
18. Lee, W.J., Wu, C.S., Lin, H., et al. (2009) Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. International Journal of Obesity (London), 33, 465-472.
19. Kim, S.R., Bae, Y.H., Bae, S.K., et al. (2008) Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochimica Biophysica Acta, 1783, 886-895.
20. Sommer, G., Kralisch, S., Stangl, V., et al. (2009) Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothelial cells. Journal of Cellular Biochemistry, 106, 729-737.
21. Gen, R., Akbay, E., Muslu, N., et al. (2009) Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecological Endocrinology, 25, 241-245.
22. Takebayashi, K., Suetsugu, M., &, Wakabayashi, S., (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism, 56, 451-458. (Pubitemid 46427838)
23. Yilmaz, M.I., Saglam, M., Carrero, J.J., et al. (2009) Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clinical Transplantation, 23, 241-248.
24. Axelsson, J., Witasp, A., Carrero, J.J., et al. (2007) Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. American Journal of Kidney Diseases, 49, 237-244. (Pubitemid 46178402)
25. Kadoglou, N.P., Gkontopoulos, A., Kapelouzou, A., et al. (2011) Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clinica Chimica Acta, 412, 48-52.
26. Doi, K., Noiri, E., &, Fujita, T., (2010) Role of vascular endothelial growth factor in kidney disease. Current Vascular Pharmacology, 8, 122-128.
27. Maeshima, Y., &, Makino, H., (2010) Angiogenesis and chronic kidney disease. Fibrogenesis Tissue Repair, 5, 13.
28. Kim, S.R., Bae, S.K., Choi, K.S., et al. (2007) Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochemical and Biophysical Research Communications, 357, 150-156.
29. Adya, R., Tan, B.K., &, Punn, A., (2008) Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovascular Research, 78, 356-365. (Pubitemid 351556097)
30. Bae, Y.H., Bae, M.K., Kim, S.R., et al. (2009) Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochemical and Biophysical Research Communications, 379, 206-211.
31. Ozkaya, M., Cakal, E., Ustun, Y., et al. (2010) Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertility Sterility, 93, 880-884.
32. Jongwutiwes, T., Lertvikool, S., Leelaphiwat, S., et al. (2009) Serum visfatin in Asian women with polycystic ovary syndrome. Gynecological Endocrinology, 25, 536-542.
33. Aigner, E., Bachofner, N., Klein, K., et al. (2009) Retinol-binding protein 4 in polycystic ovary syndrome-association with steroid hormones and response to pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism, 94, 1229-1235.
34. MacLaren, R., Cui, W., &, Cianflone, K., (2007) Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obesity and Metabolism, 9, 490-497. (Pubitemid 47018512)
35. Barber, T.M., Wass, J.A., McCarthy, M.I., et al. (2007) Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clinical Endocrinology (Oxf), 66, 513-517. (Pubitemid 46434931)